TITRE III: Influenza B Immunogenicity Investigation

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

April 12, 2019

Study Completion Date

June 30, 2025

Conditions
Influenza
Interventions
BIOLOGICAL

2018-19 quadrivalent inactivated influenza vaccine

A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine

Trial Locations (1)

V5Z 4R4

British Columbia Centre for Disease Control, Vancouver

All Listed Sponsors
collaborator

Vaccine Evaluation Center, Canada

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Institut National en Santé Publique du Québec

OTHER

lead

British Columbia Centre for Disease Control

OTHER_GOV